AMANDA SUAREZ: Open Payments
NPI 1851932115 · TULSA, OK. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,143 in 59 payments from 10 companies in 2025. Trend: 2023 $638 · 2024 $1,130 · 2025 $1,143
Food & beverage: $1,143
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 13 | $346 |
| ABBVIE INC. | 20 | $310 |
| Neurocrine BioSciences, Inc. | 14 | $147 |
| Vanda Pharmaceuticals Inc. | 1 | $122 |
| Braeburn Inc. | 3 | $67 |
| Indivior Inc. | 3 | $46 |
| Janssen Pharmaceuticals, Inc | 2 | $43 |
| Otsuka America Pharmaceutical, Inc. | 1 | $23 |
| E.R. Squibb & Sons, L.L.C. | 1 | $20 |
| Alkermes, Inc. | 1 | $19 |
Products named: VRAYLAR, AUSTEDO XR, INGREZZA, FANAPT, BRIXADI, UZEDY, SUBLOCADE, INVEGA SUSTENNA.
Industry payments across OK — which companies pay providers there.
